mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Antidepressant Action of Ketamine: In contrast to the weeks or months of treatment required for standard antidepressant medication, ketamine administration produces an antidepressant response within 4 to 6 hours in depressed patients. What lies behind the rapid actions of ketamine? Li et al. (p. 959 ; see the Perspective by Cryan and O'Leary ) found that ketamine administration resulted in fast activation of mammalian target of rapamycin (mTOR) signaling and increased levels of synaptic proteins in the rat prefrontal cortex. Ketamine rapidly increased the density and function of the dendritic spines of layer V pyramidal neurons in the prefrontal cortex. Thus, the behavioral actions of ketamine in models of depression and antidepressant response are dependent on mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have suggested that ketamine can increase the synthesis of synaptic proteins through BDNF signaling dependent on the activate protein kinase B (Akt) and mammalian target of rapamycin complex 1 (mTORC1) signaling cascades. 378 , 379”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esmethadone can also alleviate neural dysfunction linked to symptoms of depression by boosting the synapse and spine density and restoring spinogenesis, in addition to correcting depressive-like behaviors in animal models of depression. 378 , 477”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine rapidly and transiently increases glutamate transmission in the PFC, possibly via inhibition of tonically active GABAergic inter-neurons, and the resulting burst of glutamate is thought to underlie ketamine induction of synapto-genesis (6, 7).”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single dose of ketamine increases BDNF release and stimulates mTORC1 signaling, which leads to increased levels of synaptic proteins (i.e., GluR1, PSD95, and synapsin 1) and increased number and function of synapses in the PFC 4,22,35 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [35]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
mTOR signaling: At the crossroads of plasticity, memory and disease
Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Functional neuroimaging studies of depression: The anatomy of melancholia
Drevets, W. C. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.341 · Cited by 500
Liu, R.-J., & Aghajanian, G. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706679105 · Cited by 346
Self-citation
Cited by
Items 101–200 of 1,062
Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4950-4 · Cited by 308
Yan, Z., & Rein, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01092-3 · Cited by 300
“Decreased levels of mTORC are found in the PFC of humans with the major depressive disorder [112], and the fast-acting antidepressant ketamine increases mTORC signaling in rat PFC [113].”
BackgroundNMDA receptors in nervous system diseases
Zhou, Q., & Sheng, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.030 · Cited by 298
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial
Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., Lener, M., Kautz, M., Kim, J., Stern, J. B., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715001506 · Cited by 297
“NMDA receptor-regulated neuroplasticity (Dwivedi et al. 2005; Li et al. 2010; Duman & Aghajanian, 2012; Kang et al. 2013) and neuroinflammatory processes (Lindqvist et al.”
BackgroundZhang, J.-C., Wu, J., Fujita, Y., Yao, W., Ren, Q., Yang, C., Li, S.-X., Shirayama, Y., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu077 · Cited by 289
“These findings suggest that both peripheral and central inflammations are associated with depressive symptoms, and it is therefore highly plausible that anti-inflammatory drugs could ameliorate depressive symptoms in these patients.”
BackgroundResultBeurel, E., Song, L., & Jope, R. S. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.47 · Cited by 288
Wohleb, E. S., Terwilliger, R., Duman, C. H., & Duman, R. S. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.026 · Cited by 288
Self-citationEpilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review
Brodie, M. J., Besag, F., Ettinger, A. B., Mula, M., Gobbi, G., Comai, S., Aldenkamp, A. P., & Steinhoff, B. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012021 · Cited by 288
“The mammalian target of rapamycin is a regulator of mRNA translation that is itself regulated by ERK and protein kinase B (Li et al., 2010).”
BackgroundAntidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
Browne, C. A., & Lucki, I. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00161 · Cited by 285
Burgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284
“IntraMPFC injections of GLYX-13 and ketamine were also administered (0.1, 1, 10 mg/side; 1 h before testing), on the basis of a previous report that the antidepressant-like effects of ketamine (10 mg/kg, IP) were blocked by MPFC injections of an mTOR inhibitor (Li et al, 2010).”
BackgroundMethodInfluentialNeuronal plasticity and neurotrophic factors in drug responses
Castrén, E., & Antila, H. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.61 · Cited by 284
Zarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
Scheidegger, M., Walter, M., Lehmann, M., Metzger, C., Grimm, S., Boeker, H., Boesiger, P., Henning, A., & Seifritz, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044799 · Cited by 282
Microglia in depression: current perspectives
Jia, X., Gao, Z., & Hu, H. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1815-6 · Cited by 282
“…activity in the mPFC (Homayoun and Moghaddam, 2007), elevated brain-derived neurotropic factor (BDNF) (Autry et al., 2011) and protein synthesis (Li et al., 2010), increased AMPAR-mediated synaptic transmission and synapse formation (Moda-Sava et al., 2019), and disinhibition of the reward…”
BackgroundNeuroplasticity Underlying the Comorbidity of Pain and Depression
Doan, L., Manders, T., & Wang, J. (2015) · Neural Plasticity · doi:10.1155/2015/504691 · Cited by 282
“of drugs that increase glutamate signaling through AMPA receptors [92, 118, 119], have demonstrated that drugs that increase glutamate signaling in the brain can also treat the depressive symptoms of chronic pain [49, 53].”
BackgroundInfluentialLinge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, A., Adell, A., & Díaz, Á. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.017 · Cited by 279
“, 2009), but also triggers an immediate antidepressant-like effect, similarly to that reported for ketamine (Li et al., 2010; Maeng et al., 2008).”
ResultNeuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
BDNF in sleep, insomnia, and sleep deprivation
Schmitt, K., Holsboer-Trachsler, E., & Eckert, A. (2016) · Annals of Medicine · doi:10.3109/07853890.2015.1131327 · Cited by 273
Depression in neurodegenerative diseases: Common mechanisms and current treatment options
Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.002 · Cited by 269
REDD1 is essential for stress-induced synaptic loss and depressive behavior
Ota, K. T., Liu, R.-J., Voleti, B., Maldonado-Aviles, J. G., Duric, V., Iwata, M., Dutheil, S., Duman, C., Boikess, S., Lewis, D. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3513 · Cited by 267
“Brain slices were prepared as previously described (14, 21).”
Self-citationmTOR: A pathogenic signaling pathway in developmental brain malformations
Crino, P. B. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.07.008 · Cited by 266
An excitatory synapse hypothesis of depression
Thompson, S. M., Kallarackal, A. J., Kvarta, M. D., Van Dyke, A. M., LeGates, T. A., & Cai, X. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.03.003 · Cited by 265
Fuchikami, M., Thomas, A., Liu, R., Wohleb, E. S., Land, B. B., DiLeone, R. J., Aghajanian, G. K., & Duman, R. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414728112 · Cited by 265
“), a dose that produces antidepressant responses (4).”
BackgroundMethodResultSelf-citationVoleti, B., Navarria, A., Liu, R.-J., Banasr, M., Li, N., Terwilliger, R., Sanacora, G., Eid, T., Aghajanian, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.025 · Cited by 264
“Our previous studies demonstrate that ketamine administration also rapidly increases the number and function of spine synapses in the PFC (10), raising the possibility that scopolamine increases spine density and function.”
InfluentialSelf-citationKetamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“The resulting increase in glutamatergic activity produces downstream activation of mammalian target of rapamycin (mTOR) function to increase dendritic spine formation and produce the rapid and sustained antidepressant effects [87, 90] (see Fig.”
BackgroundEmerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity
Gerhard, D. M., Wohleb, E. S., & Duman, R. S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.016 · Cited by 261
“Corresponding to these clinical findings, animal models show that, like ketamine, scopolamine caused rapid antidepressant responses through increased glutamate neurotransmission and activation of mTORC1 signaling in the PFC [9, 54].”
BackgroundInfluentialSelf-citationDe Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 259
“AMPARs mediate ketamine-induced synaptic facilitation in the mPFC and hippocampus (Li et al., 2010; Zanos et al., 2016; for review, see also Aleksandrova et al., 2017).”
InfluentialSynaptic Mechanisms Underlying Rapid Antidepressant Action of Ketamine
Kavalali, E. T., & Monteggia, L. M. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040531 · Cited by 258
Larkin, G. L., & Beautrais, A. L. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 258
“The mechanism of ketamine’s rapid antidepressant and anti-suicidal actions are unclear but appear to be related to glutamate neurotransmission (Li et al. 2010; Mathew et al. 2009; Zarate et al. 2006).”
BackgroundRetractedSpine synapse remodeling in the pathophysiology and treatment of depression
Duman, C. H., & Duman, R. S. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.01.022 · Cited by 257
Self-citationPsychoplastogens: A promising class of plasticity-promoting neurotherapeutics
Olson, D. E. (2018) · Journal of Experimental Neuroscience · doi:10.1177/1179069518800508 · Cited by 257
Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior
Brachman, R. A., McGowan, J. C., Perusini, J. N., Lim, S. C., Pham, T. H., Faye, C., Gardier, A. M., Mendez-David, I., David, D. J., Hen, R., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.022 · Cited by 257
“Additionally, ketamine has been shown to induce rapid and persistent remodeling of synapses (45).”
BackgroundLiu, R.-J., Fuchikami, M., Dwyer, J. M., Lepack, A. E., Duman, R. S., & Aghajanian, G. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.128 · Cited by 256
Self-citationDuncan, W. C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B. A., Hejazi, N. S., Yuan, P., Brutsche, N., Manji, H. K., Tononi, G., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000545 · Cited by 256
“Preclinical studies found that ketamine injections increased synaptic strength in rat prefrontal cortex, as reflected by : (a) enhanced postsynaptic protein signalling ; (b) increased synaptogenesis ; (c) enhanced excitatory post-synaptic currents (Li et al. 2010).”
Zarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255
“Preclinical studies have postulated that the mechanism of action of ketamine is initially mediated by NMDA antagonism but subsequently involves enhanced a-amino-3-hydroxyl-5methyl-4-isoxazole-propionate (AMPA) throughput (12) and, in turn, activates mammalian target of rapamycin (13).”
Localized connectivity in depression: A meta-analysis of resting state functional imaging studies
Iwabuchi, S. J., Krishnadas, R., Li, C., Auer, D. P., Radua, J., & Palaniyappan, L. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.01.006 · Cited by 255
Dendritic spines: Revisiting the physiological role
Chidambaram, S. B., Rathipriya, A. G., Bolla, S. R., Bhat, A., Ray, B., Mahalakshmi, A. M., Manivasagam, T., Thenmozhi, A. J., Essa, M. M., Guillemin, G. J., et al. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.01.005 · Cited by 255
Ketamine: NMDA Receptors and Beyond
Zorumski, C. F., Izumi, Y., & Mennerick, S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1547-16.2016 · Cited by 254
“Importantly, the psychiatric effects of ketamine are observed at subanesthetic doses (Li et al., 2010; Abdallah et al., 2015) that likely achieve brain concentrations in the low micromolar range, although actual brain concentrations remain uncertain (Hartvig et al.”
BackgroundResultInfluentialHaile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., Iqbal, S., Mahoney, J. J., De La Garza, R., Charney, D. S., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001119 · Cited by 253
“Preclinical studies indicate that NMDA receptor blockade leads to upregulation in AMPA receptor expression and subsequent activation of the mammalian target of rapamycin (mTOR) intracellular cascade that is required for ketamine’s antidepressant action (Li et al., 2010).”
BackgroundAntidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Sex differences in the antidepressant-like effects of ketamine
Carrier, N., & Kabbaj, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.12.009 · Cited by 251
“, 2004) as well as by acute ketamine treatment (Li et al., 2010).”
BackgroundMethodInfluentialKetamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects
Nugent, A. C., Ballard, E. D., Gould, T. D., Park, L. T., Moaddel, R., Brutsche, N. E., & Zarate, C. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0028-2 · Cited by 250
Yang, C., Ren, Q., Qu, Y., Zhang, J.-C., Ma, M., Dong, C., & Hashimoto, K. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.016 · Cited by 250
Duman, R. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.1/rduman · Cited by 249
“However, preliminary studies have failed to demonstrate an effect of a single electroconvulsive seizure on mTORC1 signaling in rodent PFC.51 Another treatment possibility is sleep deprivation, which is reported to influence mTORC1 signaling in the mouse hippocampus, but mTORC1 was decreased, not increased.93 Further s…”
BackgroundSelf-citationMolecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
Feder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20050596 · Cited by 246
“…a rapid increase in glutamate release, triggering several downstream signaling pathways (including brain-derived neurotrophic factor [BDNF] and mammalian target of rapamycin complex 1 [mTORC1]), resulting in increased synaptogenesis and synaptic spine maturation in key brain regions (33, 34).”
BackgroundKetamine: A tale of two enantiomers
Jelen, L. A., Young, A. H., & Stone, J. M. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959644 · Cited by 246
“Work in rodents initially demonstrated that (R,S)-ketamine rapidly activated the mTORC pathway, leading to increased synaptic signalling proteins and synaptic spine density (Li et al., 2010).”
BackgroundResultInfluentialSanacora, G., & Banasr, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.032 · Cited by 239
“However, it is possible that the rapid increase in glutamate release and stimulation of post-synaptic AMPA receptors following NMDAR antagonist treatment, now believed to be critical for the antidepressant effects of the drugs (92, 93) (see Krystal et al.”
BackgroundSelf-citationKetamine for Treatment-Resistant Unipolar Depression: Current Evidence
Mathew, S. J., Shah, A., Lapidus, K., Clark, C., Jarun, N., Ostermeyer, B., & Murrough, J. W. (2012) · CNS Drugs · doi:10.2165/11599770-000000000-00000 · Cited by 238
“The study by Li et al.([130]) also reported that the molecular and behavioural effects of ketamine were blocked by an AMPA receptor antagonist (NBQX), extending a previous report.”
BackgroundBeaulieu, J.-M. (2012) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.110011 · Cited by 238
Sanacora, G., Smith, M. A., Pathak, S., Su, H.-L., Boeijinga, P. H., McCarthy, D. J., & Quirk, M. C. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.130 · Cited by 236
Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine
Hashimoto, K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113935 · Cited by 236
The role of ketamine in treatment-resistant depression: A systematic review
Serafini, G., Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140619204251 · Cited by 234
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang-Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 234
Muthukumaraswamy, S. D., Shaw, A. D., Jackson, L. E., Hall, J., Moran, R., & Saxena, N. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0903-15.2015 · Cited by 234
“This activation includes an increase in the mTOR signaling pathway, which is necessary for the antidepressant response (Li et al., 2010).”
BackgroundGideons, E. S., Kavalali, E. T., & Monteggia, L. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323920111 · Cited by 232
“The rapid antidepressant effects of ketamine have also been suggested to be mediated by mammalian target of rapamycin (mTOR)-dependent synapse formation, although it remains unclear how blockade of the NMDAR activates mTOR (30).”
BackgroundPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Prévot, T., & Sibille, E. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0727-3 · Cited by 231
Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial
Nagele, P., Duma, A., Kopec, M., Gebara, M. A., Parsoei, A., Walker, M., Janski, A., Panagopoulos, V. N., Cristancho, P., Miller, J. P., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.016 · Cited by 230
Sex differences in antidepressant efficacy
LeGates, T. A., Kvarta, M. D., & Thompson, S. M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0156-z · Cited by 230
Aleksandrova, L. R., Phillips, A. G., & Wang, Y. T. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160175 · Cited by 228
Belujon, P., & Grace, A. A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.014 · Cited by 225
“Ketamine rapidly reverses the stress-induced deficit in spine density (6) by activation of the mammalian target of rapamycin signaling pathway (4,6,7).”
InfluentialMechanism of action of ketamine
Stahl, S. M. (2013) · CNS Spectrums · doi:10.1017/s109285291300045x · Cited by 52
“Increase in synaptic spines can be seen in experimental animals very soon after ketamine administration.(5) One hypothesis is that it is actually this increase in dendritic spines that causes the rapid onset antidepressant effect, and not just the blockade of NMDA receptors or the stimulation of AMPA receptors.”
BackgroundInfluentialShiroma, P. R., Johns, B., Kuskowski, M., Wels, J., Thuras, P., Albott, C. S., & Lim, K. O. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.036 · Cited by 221
“However, these agents target only monoamines, which are modulatory transmitters, and may not exert a profound effect over synaptic transmission, activitydependent release of BDNF, and synaptogenesis as ketamine does (Duman et al., 2012; Kavalali and Monteggia, 2012; Li et al., 2010).”
BackgroundIbrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220
“In addition, the selective NR2B antagonist Ro25-6981was found to activate themammalian target of rapamycin, a protein that has been linked to the antidepressant effects of ketamine(13) and, in preclinical rodent studies, was found to have significant antidepressant-like properties.(13,14) Recently, the NR2B subunit se…”
BackgroundMathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
“Specifically, ketamine was found to transiently increase the phosphorylated and activated forms of eukaryotic initiation factor 4E binding protein 1 (4E-BP1), p70S6 kinase (p70S6K) and mTOR.([105]) These proteins are all involved in the mTORsignalling pathway and serve as prominent regulators of protein translation.”
BackgroundResultInfluentialThe role of dissociation in ketamine’s antidepressant effects
Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 220
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.010 · Cited by 219
Self-citationGlutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
Hashimoto, K., Malchow, B., Falkai, P., & Schmitt, A. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0399-y · Cited by 219
“of mTOR signaling in the antidepressant effects of ketamine [96, 97].”
BackgroundHare, B. D., Shinohara, R., Liu, R. J., Pothula, S., DiLeone, R. J., & Duman, R. S. (2019) · Nature Communications · doi:10.1038/s41467-018-08168-9 · Cited by 217
Self-citationBalu, D. T., Li, Y., Puhl, M. D., Benneyworth, M. A., Basu, A. C., Takagi, S., Bolshakov, V. Y., & Coyle, J. T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304308110 · Cited by 217
“Local protein synthesis is necessary for dendritic plasticity (62), as activation of the Akt/mTOR/p70S6K pathway increases dendritic arborization and spine density (63, 64).”
BackgroundNeuroscience of Behavioral and Pharmacological Treatments for Addictions
Potenza, M. N., Sofuoglu, M., Carroll, K. M., & Rounsaville, B. J. (2011) · Neuron · doi:10.1016/j.neuron.2011.02.009 · Cited by 214
“Additionally, investigating means for altering synaptic connections, including rapid mechanisms related to brief exposure to antiglutamatergic drugs (Li et al., 2010), may aid addiction treatment development efforts, particularly as related to stress or other negative reinforcement processes.”
Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F. J., Sanacora, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.031 · Cited by 213
“Ongoing studies are investigating the cellular and molecular mechanisms underlying ketamine’s beneficial effects (4,5), with a view to both expanding our understanding of affective disorders and developing effective, viable, and rapid-acting treatments.”
BackgroundDuman, R. S. (2014) · Depression and Anxiety · doi:10.1002/da.22227 · Cited by 213
“Evidence that mTORC1 plays a functional role in the response to ketamine is provided by studies demonstrating that rapamycin, a selective inhibitor of mTORC1, blocks the synaptogenic and behavioral actions of ketamine.[20, 21] Further studies have focused on the signaling pathways that stimulate mTORC1, including the…”
BackgroundSelf-citationPsychedelic-inspired drug discovery using an engineered biosensor
Dong, C., Ly, C., Dunlap, L. E., Vargas, M. V., Sun, J., Hwang, I.-W., Azinfar, A., Oh, W. C., Wetsel, W. C., Olson, D. E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.043 · Cited by 213
Page, C. E., & Coutellier, L. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.07.024 · Cited by 213
Brain NMDA Receptors in Schizophrenia and Depression
Adell, A. (2020) · Biomolecules · doi:10.3390/biom10060947 · Cited by 212
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide
Duman, R. S. (2018) · F1000Research · doi:10.12688/f1000research.14344.1 · Cited by 207
“…of chronic stress, we found that a single dose of ketamine rapidly increases the number and function of spine synapses in layer V pyramidal neurons in the medial PFC (mPFC) and rapidly reverses the synaptic deficits of these neurons caused by 3 weeks of chronic stress exposure 18,19 (Figure 1).”
BackgroundInfluentialSelf-citationKETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS
Abdallah, C. G., Adams, T. G., Kelmendi, B., Esterlis, I., Sanacora, G., & Krystal, J. H. (2016) · Depression and Anxiety · doi:10.1002/da.22501 · Cited by 206
“Blockage of mTOR signaling blocks ketamine-induced synaptogenesis and ketamine’s antidepressant-like effects.[39] Ketamine”
InfluentialHibicke, M., Landry, A. N., Kramer, H. M., Talman, Z. K., & Nichols, C. D. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00493 · Cited by 205
Widman, A. J., & McMahon, L. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718883115 · Cited by 204
“At higher concentrations, ketamine decreases excitatory transmission (40) and has no antidepressantlike effects in rodent models (7), so the concentration used is critical.”
BackgroundFuchs, T., Jefferson, S. J., Hooper, A., Yee, P.-H., Maguire, J., & Luscher, B. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.188 · Cited by 204
“Behavioral changes in the NSFT analogous to those of SSTCre: γ 2 f/f mice are observed following chronic but not acute administration of conventional antidepressants 66, 67 , as well as after an acute dose of ketamine 29, 32 .”
InfluentialSustained antidepressant effect of ketamine through NMDAR trapping in the LHb
Ma, S., Chen, M., Jiang, Y., Xiang, X., Wang, S., Wu, Z., Li, S., Cui, Y., Wang, J., Zhu, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06624-1 · Cited by 204
“The burst signatures provided in the methods differ from previous work published by the authors, thus this makes difficult to compare across literature.”
BackgroundMethodThe hippocampus and TNF: Common links between chronic pain and depression
Fasick, V., Spengler, R. N., Samankan, S., Nader, N. D., & Ignatowski, T. A. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.014 · Cited by 204
Valentine, G. W., Mason, G. F., Gomez, R., Fasula, M., Watzl, J., Pittman, B., Krystal, J. H., & Sanacora, G. (2011) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2010.10.009 · Cited by 204
“In addition, recent studies suggest that increased alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-receptor-mediated synaptic potentiation and subsequent activation of the mTOR signaling pathway initiate the physiological responses that generate ketamine's antidepressantlike actions in rodent models (…”
BackgroundTargeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders
Hayashi, T., Tsai, S.-Y., Mori, T., Fujimoto, M., & Su, T.-P. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.560837 · Cited by 204
“It is noteworthy that mTOR-p70S6k-dependent synapse formation has been recently discovered to be a key element of the rapid antidepressant-like action of drugs [42], and that one of the most unique actions of Sig-1R agonists is their rapid antidepressant-like effect as proven by several studies [11].”
Backgroundde Theije, C. G. M., Wu, J., da Silva, S. L., Kamphuis, P. J., Garssen, J., Korte, S. M., & Kraneveld, A. D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.07.013 · Cited by 202
“mTOR inhibition with rapamycin blocked synaptic protein synthesis and antidepressant behavioral responses in rats (Li et al., 2010).”
BackgroundInfluentialIadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201
“Ketamine increased mTOR phosphorylation and other downstream molecular targets critical for transcriptional activation within 1 hour of administration [Li et al. 2010].”
BackgroundClinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Cell atrophy and loss in depression: reversal by antidepressant treatment
Banasr, M., Dwyer, J. M., & Duman, R. S. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.002 · Cited by 201
Self-citationMiller, O. H., Moran, J. T., & Hall, B. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.028 · Cited by 200
Cornwell, B. R., Salvadore, G., Furey, M., Marquardt, C. A., Brutsche, N. E., Grillon, C., & Zarate, C. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.029 · Cited by 200
NMDA Receptors in the Central Nervous System
Hansen, K. B., Yi, F., Perszyk, R. E., Menniti, F. S., & Traynelis, S. F. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7321-7_1 · Cited by 199
Ghosal, S., Hare, B. D., & Duman, R. S. (2017) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.09.012 · Cited by 199
Self-citationSales, A. J., Fogaça, M. V., Sartim, A. G., Pereira, V. S., Wegener, G., Guimarães, F. S., & Joca, S. R. L. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1143-4 · Cited by 198
Franceschelli, A., Sens, J., Herchick, S., Thelen, C., & Pitychoutis, P. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.008 · Cited by 198
“(2010) showed that the rapid antidepressant effect of a single dose of ketamine in male rats is mediated through the induction of synaptogenesis in the PFC, a brain region implicated in the pathophysiology of major depression (Li et al., 2010).”
InfluentialChowdhury, G. M. I., Zhang, J., Thomas, M., Banasr, M., Ma, X., Pittman, B., Bristow, L., Schaeffer, E., Duman, R. S., Rothman, D. L., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.34 · Cited by 197
Self-citationThe stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders
Sanacora, G., Yan, Z., & Popoli, M. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00540-x · Cited by 197
Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines
Ali, F., Gerhard, D. M., Sweasy, K., Pothula, S., Pittenger, C., Duman, R. S., & Kwan, A. C. (2020) · Nature Communications · doi:10.1038/s41467-019-13809-8 · Cited by 196
Self-citation
Metadata
- Authors
- Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S.
- Affiliations
- Yale University (US)
- Laboratory of Molecular Psychiatry, Center for Genes and Behavior, Departments of Psychiatry and Neurobiology, Yale University School of Medicine, 34 Park Street, New Haven, CT 06508, USA.
- Corresponding author
- Duman, Ronald S.
- Venue
- Science
- Published
- 2010-08-20
- Volume
- 329
- Issue
- 5994
- Pages
- 959-964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3116441
- OpenAlex
- W2089351762
- Cited by
- 2,881
- References
- 14
- Citations by year
- 2026: 147 · 2025: 161 · 2024: 171 · 2023: 175 · 2022: 218 · 2021: 234 · 2020: 233 · 2019: 202 · 2018: 199 · 2017: 171 · 2016: 205 · 2015: 217 · 2014: 136 · 2013: 153 · 2012: 125
- FWCI
- 96.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute of Mental Health (2P01 MH25642, MH-45481, P01MH025642, R01MH045481)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, mTOR signaling, synaptogenesis, NMDA receptor antagonists, rapid antidepressant effects, treatment-resistant depression, prefrontal cortex, dendritic spines, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Male, Neurons, Neuropeptides, Phenols, Piperidines, Synapses, Time Factors, Protein Biosynthesis, Signal Transduction, Receptors, N-Methyl-D-Aspartate, Rats, Sprague-Dawley, Protein Serine-Threonine Kinases, Sirolimus, Intracellular Signaling Peptides and Proteins, Dendritic Spines, Rats, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.